GLP-1 effects on food intake and body weight One of the most frequently described extrapancreatic effects of pharmacokinetically-optimized GLP-1R analogs is their ability to lower body weight via centrally regulated inhibition of food intake (Figure 7)
Instead, they work by: Slowing down melanin production Supporting skin renewal Strengthening the skin barrier 1
Novo initially held an advantage over Lilly, as WEGOVY entered the market before Lillys competing drug, ZEPBOUND, and secured broader insurance coverage early on
Under the brand name Wegovy, it is indicated for weight management in non-diabetic populations with weight-related comorbidities [6, 7]
Studies suggest it may help with: Tissue repair and regeneration Muscle and tendon recovery Joint and ligament support Gut health and digestive balance Reducing inflammation and speeding recovery Due to these potential benefits, BPC-157 is often used under professional guidance for injury and recovery support
